Furthermore, treated animals displayed higher absolute numbers of CD4+ and CD8+ T cells producing IFN-γ and TNF-α, particularly after anti-CD3 stimulation.<h4>Conclusions</h4>Treatment with β-GESc demonstrates immunomodulatory potential by increasing both splenic and systemic cell frequencies, contributing to the control of experimental melanoma. The gene discussed is CD4; the disease is melanoma.